Good morning!

Cyprotex (LON:CRX)

This is a new one to me, Cyprotex (LON:CRX) is a ££29.2m (at 12.25p) market cap medical (and other sectors) screening services company, which reports today on trading for the year ended 31 Dec 2013.

It says that trading for 2013 was slightly ahead of market expectations, with turnover up 17% to £9.8m. Pre-exceptional profit is expected to be between £750-850k, up strongly from £326k in 2012, which it puts down to high operational gearing (i.e. high margins on sales & mostly fixed costs).

Adjusted EBITDA is reported to also be slightly ahead of expectations, at £1.5-1.6m. Personally I'm not a fan of EBITDA, unless a business is mature and needs to do very little capex in the future. Otherwise, relying on EBITDA really just means that you're ignoring a whole set of costs, which will inevitably lead to people over-valuing a company. Although it can be a quick proxy for cash generation in certain circumstances.

The market cap of £29.2m looks rather high to me, given profit is under £1m, so that factors in quite a bit of growth. Looking at the Stockopedia StockReport, I see that the average number of shares has increased every year since 2007, at an average compound growth rate of about 9% p.a. So shareholders are seeing gradual dilution there, despite the company being generally profitable throughout that period.

So that probably means the company has been making aquisitions, therefore I would want to check how much growth had been organic, and how much has come from acquisitions. In my view many investors are over-paying for acquisitive companies, thinking that growth has been organic, whereas often it hasn't.

That reminds me of a terrible investing mistake that I made in 2006 or 2007 due to this - I piled into a company called TMN, thinking that they looked cheap for a growth company. It was only when I'd acquired a stake of about £250k that I realised the growth had been through bolt-on acquisitions. The shares almost collapsed in the credit crunch, and I lost nearly all my investment. So another very important lesson, as always, learned the hard way - to properly do the research before committing significant funds, and to cover every angle.

Another important point, flagged in today's statement from Cyprotex, is that they entered into a financing arrangement…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here